<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625322</url>
  </required_header>
  <id_info>
    <org_study_id>20-5188</org_study_id>
    <nct_id>NCT04625322</nct_id>
  </id_info>
  <brief_title>HCV Treatment Initiation During Acute Psychiatric Admission</brief_title>
  <official_title>INSPIRE: Interventions for Screening and Treatment of Psychiatric Inpatients With HCV Resulting in Elimination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing&#xD;
      substance use and mental health challenges. In the past, many individuals with mental illness&#xD;
      were not treated due to the psychiatric side-effects of interferon. However, the development&#xD;
      of highly effective, direct-acting antivirals (DAA) has revolutionized HCV treatment such&#xD;
      that cure rates are &gt;95% with 8-12 weeks of simple, safe, and well-tolerated therapy.&#xD;
&#xD;
      A recent systematic review reported that across 13 North American studies, HCV prevalence&#xD;
      among people admitted to psychiatric hospitals was a staggering 17.4% (13.2-22.6%). Despite&#xD;
      these concerning figures, mental health facilities have not been a focus of HCV elimination&#xD;
      efforts to date. The Centre for Addiction and Mental Health (CAMH) in Toronto is the largest&#xD;
      mental health facility in Canada, with a psychiatric emergency department seeing ~35 patients&#xD;
      per day with many admitted to the acute psychiatric units for safety and stabilization.&#xD;
      Currently, psychiatric patients screened for HCV at CAMH have a 75% 'no show' rate at the&#xD;
      Toronto Centre for Liver Disease (TCLD), which is located less than 5km away, suggesting that&#xD;
      referral upon discharge is ineffective.&#xD;
&#xD;
      This study will be the first trial to evaluate whether it would be feasible and beneficial to&#xD;
      initiate treatment during an acute psychiatric admission rather than referring to specialty&#xD;
      upon discharge. The combination of broad HCV screening with rapid linkage to treatment has&#xD;
      led to successful elimination of HCV within defined populations, so-called micro-elimination.&#xD;
      The investigators hypothesize that HCV treatment can be effectively delivered by providers in&#xD;
      psychiatric care facilities, which will improve treatment uptake over traditional referral&#xD;
      models.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Models of Care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12 by intention to treat (ITT) in each arm</measure>
    <time_frame>24 months</time_frame>
    <description>To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by intention to treat (ITT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR12 by modified intention to treat (mITT) in each arm</measure>
    <time_frame>24 months</time_frame>
    <description>To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by modified intention to treat (mITT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV relapse rate</measure>
    <time_frame>24 months</time_frame>
    <description>To compare the HCV viral relapse rate in both arms (re-appearance of HCV RNA in those undetectable at end of treatment; relapse distinguished from reinfection by sequencing of the recurrent HCV RNA and comparing to baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV seroprevalence rates</measure>
    <time_frame>12 months</time_frame>
    <description>To determine HCV seroprevalence rates among acute vs addictions patients admitted to CAMH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA positivity rates</measure>
    <time_frame>12 months</time_frame>
    <description>To determine HCV RNA positivity rates among acute vs addictions patients admitted to CAMH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAMH staff acceptability of POC antibody and RNA testing</measure>
    <time_frame>12 months</time_frame>
    <description>CAMH staff involved in the trial will be asked to particiapte in an acceptibility survey regarding rapid POC antibody and RNA testing on the acute units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of POC HCV RNA with HCV RNA by phlebotomy</measure>
    <time_frame>12 months</time_frame>
    <description>To determine concordance of POC HCV RNA (GeneXpert) with HCV RNA by phlebotomy (Abbott RealTime).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum and mean times from diagnosis to treatment initiation</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the mean and minimum times to treatment initiation in both arms, and compare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence with out-patient follow-up visits</measure>
    <time_frame>24 months.</time_frame>
    <description>Evaluate and compare out-patient follow-up visit adherence in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to HCV treatment, by HCV regimen</measure>
    <time_frame>24 months.</time_frame>
    <description>Evaluate and compare both arms for medication adherence (patient self-report and pill count), and variance by medication regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events while on HCV treatment</measure>
    <time_frame>18 months.</time_frame>
    <description>To determine and compare adverse events in both arms while patients are on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV Reinfection</measure>
    <time_frame>24 months.</time_frame>
    <description>Reinfection rates by the end of the defined as HCV RNA detectability after prior SVR with demonstration of distinct viral sequence from baseline sample to distinguish</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Referral to outpatient specialty for HCV care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receive HCV care during inpatient admission by a hospitalist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HCV care provided by hospitalist during acute psychiatric admission</intervention_name>
    <description>HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH</description>
    <arm_group_label>Receive HCV care during inpatient admission by a hospitalist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic HCV infection, positive HCV RNA&#xD;
&#xD;
          2. Aged 18 to 80&#xD;
&#xD;
          3. Willingness and capacity to provide informed consent, or consent is provided by a&#xD;
             substitute decision maker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of or history of decompensated cirrhosis (evidence of decompensation with&#xD;
             history of either ascites, variceal hemorrhage, or hepatic encephalopathy)&#xD;
&#xD;
          2. Platelets &lt; 75,000/mm3, total albumin &lt;35 g/L, total bilirubin &gt;34 Î¼mol/L, INR &gt;1.5&#xD;
&#xD;
          3. History of current or past hepatocellular carcinoma.&#xD;
&#xD;
          4. HBV (HBsAg +ve) co-infection or untreated HIV co-infection&#xD;
&#xD;
          5. Prior HCV antiviral therapy with DAA with or without peginterferon/ribavirin&#xD;
&#xD;
          6. Chronic liver disease other than mild nonalcoholic or alcoholic fatty liver disease&#xD;
             from a cause other than HCV&#xD;
&#xD;
          7. Pregnancy/breastfeeding/inability to use contraception&#xD;
&#xD;
          8. Use of concomitant contraindicated medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brett Wolfson-Stofko, PhD</last_name>
    <phone>4163404800</phone>
    <phone_ext>8842</phone_ext>
    <email>brett.wolfson-stofko@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mia J Biondi, NP-PHC, PhD</last_name>
    <phone>6476286461</phone>
    <email>mia.biondi@mail.mcgill.ca</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Psychiatric</keyword>
  <keyword>Hospital</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

